Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1025)	4/25/2000 7:57:00 AM
From: Jim Oravetz	Respond to of 52153

What?s Next for Biotech Funds? ....All five of the specialized funds followed by Morningstar were down 26.66 percent or more in the four weeks ended April 14. The sharp rebound in the Nasdaq has helped reclaim some of those losses. By April 18, Fidelity Select Biotechnology {FBIOX} was off only 13 percent for the trailing month, and Rydex Biotechnology {RYOIX} was off only 8 percent following the two-day recovery that started the week. Year-to-date, the Fidelity fund is flat and the Rydex is up 5 percent, but these short-range swings are something die-hard biotech investors are going to have to get used to..... cnbc.com Jim